Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522269

Integrated Psychological, Anesthetic, Nursing, and General Practice Approaches to the Management of Complex Regional Pain Syndrome

Mousa Abdo Mansor Hanbashi [(1)] , Hisham Mohamed Ali Moaafa [(2)] , Turki Ali Mohammed Alhuzaim [(3)] , Basem Ali Hassan Harbi [(4)] , Fahad Mohammed Faqihi [(5)] , Aljawharah Saad Alrasheed [(6)] , Wafa Abdullah Alolaiq , Ahmed Ghali Aladhab [(7)] , Dakheel Maashi D Alshammari [(8)] , Meznah Ageel Oudah Al Hazmi [(9)] , Mohammed Saad Alhelal [(10)]

(1) King Fahad Central Hospital- Jazan, Ministry of Health, Saudi Arabia,
(2) Damad General Hospital Jizan - Damad, Ministry of Health, Saudi Arabia,
(3) Dasman Health Center In Al Quwayiyah, Ministry of Health, Saudi Arabia,
(4) Irada Hospital And Mental Health, Ministry of Health, Saudi Arabia,
(5) General Directorate Of Prison Health , Ministry Of Health, Saudi Arabia,
(6) King Abdullah Bin Abdulaziz University Hospital , Ministry of Health, Saudi Arabia,
(7) King Fahad Phc, Ministry of Health, Saudi Arabia,
(8) Hail Health Cluster Qassir Bin Matrouk Health Center, Ministry of Health, Saudi Arabia,
(9) Heart Canter At King Abdulaziz Specialist Hosiptal In Al-Jouf, Ministry of Health, Saudi Arabia,
(10) Al Omran General Hospital , Ministry of Health, Saudi Arabia

Abstract

Background: Complex Regional Pain Syndrome (CRPS) is a debilitating chronic pain condition characterized by severe, disproportionate pain and a constellation of sensory, autonomic, motor, and trophic disturbances. It typically develops after a minor injury or surgery, with a pathophysiology involving neurogenic inflammation, peripheral and central sensitization, autonomic dysregulation, and immune system involvement.

Aim: This article aims to provide a comprehensive review of CRPS, synthesizing current evidence on its etiology, epidemiology, and the underlying pathophysiological mechanisms. Its primary focus is to outline a holistic, integrated management approach that combines medical, rehabilitative, psychological, and interventional strategies.

Methods: The study is a detailed narrative review, consolidating evidence from clinical studies, systematic reviews, and expert guidelines. It evaluates diagnostic criteria (notably the Budapest Criteria), various treatment modalities including physical therapy, pharmacotherapy, psychological interventions, and neuromodulation techniques like spinal cord stimulation.

Results: The review finds that CRPS is a multifactorial disorder with no single curative treatment. Effective management hinges on early diagnosis and a proactive, multidisciplinary strategy. Core components include physical and occupational therapy to restore function, pharmacotherapy (e.g., corticosteroids, bisphosphonates, anticonvulsants) for symptom control, and psychological support to address pain-related distress. For refractory cases, interventional procedures such as sympathetic nerve blocks or neuromodulation can provide significant pain relief and improve quality of life.

Conclusion: A coordinated, interprofessional approach is fundamental to managing CRPS, offering the best opportunity to reduce pain, prevent disability, and improve patient outcomes.

Keywords: Complex Regional Pain Syndrome, Neuropathic Pain, Multidisciplinary Pain Management, Central Sensitization, Budapest Criteria, Neuromodulation

Introduction

Complex regional pain syndrome (CRPS) is a chronic neuropathic pain disorder characterized by persistent, often severe pain that is disproportionate in both intensity and duration to the initial tissue injury and extends well beyond the expected period of normal tissue healing.[1] The pain is typically regional rather than focal and does not conform to a single dermatome, myotome, or peripheral nerve distribution, reflecting its complex pathophysiological basis.[1] Clinically, CRPS is distinguished by the coexistence of sensory, motor, autonomic, and trophic disturbances, which contribute to its highly disabling nature. Sensory manifestations commonly include allodynia—pain due to normally non-painful stimuli—and hyperalgesia, in which painful stimuli evoke exaggerated responses.[1][2] Autonomic and vasomotor abnormalities, such as temperature asymmetry, color changes, and altered sweating, are frequently accompanied by edema, skin and nail changes, and alterations in hair growth, collectively

*Corresponding author e-mail: Mhanbashi@moh.gov.sa (Mousa Abdo Mansor Hanbashi).
Receive Date: 01 November 2025, Revise Date: 23 November 2025, Accept Date: 24 November 2025

referred to as trophic changes.[2][3] These features may fluctuate over time and contribute to substantial functional impairment. CRPS most often develops following a precipitating event, typically trauma, fracture, surgery, or even minor soft-tissue injury, although the severity of the initiating insult often appears trivial compared to the degree of pain and dysfunction that ensue.[2][3] In some cases, no clear inciting event can be identified, and so-called "spontaneous" presentations have been reported, underscoring the multifactorial and incompletely understood mechanisms underlying the syndrome.[4] The evolution of CRPS is frequently subacute, with symptoms emerging weeks after the initial insult, progressing through phases that may include an early "warm," inflammatory state and a later "cold," atrophic phase, although such patterns are not universal.[8]

Historically, the condition that is now termed CRPS has been recognized for centuries. Ambroise Paré, in the 16th century, described patients who developed severe limb pain, swelling, and dysfunction after phlebotomy, in retrospect consistent with CRPS-like phenomena.[5] In the 19th century, Silas Weir Mitchell observed similar syndromes in soldiers with limb injuries from gunshot wounds during the American Civil War and introduced the term "causalgia" in 1872 to capture the intense burning pain and autonomic disturbances that characterized these cases.[6] Subsequently, in 1946, James A. Evans coined the term "reflex sympathetic dystrophy," reflecting the then-prevailing belief that abnormal sympathetic nervous system activity was central to the pathogenesis of the disorder.[6] As understanding evolved, it became apparent that the syndrome encompassed a broader spectrum of manifestations and was not solely dependent on sympathetic dysfunction. In 1994, the International Association for the Study of Pain (IASP) proposed the term complex regional pain syndrome to unify these historical entities and introduced diagnostic criteria that distinguished CRPS type 1 (formerly reflex sympathetic dystrophy) from CRPS type 2 (formerly causalgia).[7] Type 1 refers to cases in which there is no demonstrable nerve injury, whereas type 2 is diagnosed when a definable nerve lesion is present.[7][8] Despite this etiologic distinction, the clinical features of types 1 and 2 are largely indistinguishable, and both typically involve a regional pattern of symptoms affecting the distal extremities, which may spread proximally or even contralaterally over time.[8] Recognition that the original IASP criteria lacked specificity led to the development of the revised "Budapest Criteria" in 2010, which are now widely used in both research and clinical practice to improve diagnostic reliability.[7]



Fig. 1: Complex Regional Pain Syndrome.

Beyond the traditional typology, CRPS is also characterized along other dimensions that have prognostic and therapeutic relevance. Clinicians often describe CRPS as "warm" or "cold," based on the predominance of inflammatory signs such as erythema and warmth versus vasoconstrictive features and limb coolness.[8] Additionally, pain may be sympathetically maintained—responding to sympathetic blocks or adrenergic modulation—or sympathetically independent, reflecting heterogeneity in underlying mechanisms and informing individualized treatment strategies.[8] These classifications underscore the complex interplay between peripheral and central sensitization, autonomic dysregulation, inflammatory processes, and psychological factors that contribute to symptom persistence and severity.[1][8] The impact of CRPS extends far beyond physical symptoms. Patients frequently experience profound functional limitations, including impaired use of the affected limb, difficulty performing activities of daily living, and reduced participation in work and social roles.[2][3] Sleep disturbances, fatigue, and reduced physical activity further exacerbate disability. Psychologically, CRPS is strongly associated with mood and anxiety disorders, fear-avoidance behaviors, catastrophizing, and reduced self-efficacy, all of which can amplify pain perception and hinder rehabilitation.[9][10][11] The chronic, unpredictable nature of the condition, coupled with diagnostic delays and uncertainty about prognosis, often contributes to frustration, distress, and diminished quality of life for patients and their families.[9][11] From a clinical standpoint, the variable presentation, overlapping features with other pain and neurological disorders, and still-elusive pathophysiology of CRPS pose significant diagnostic and therapeutic challenges.[1][4][8] Early recognition and timely, multidisciplinary intervention—integrating medical, psychological, and rehabilitative approaches—are

therefore essential to mitigate chronicity, prevent secondary complications such as disuse and contractures, and address the substantial psychosocial burden associated with this complex pain syndrome.[9][10][11]

Etiology

Complex regional pain syndrome (CRPS) most commonly develops following tissue trauma, yet the severity of the inciting event is often strikingly disproportionate to the intensity and chronicity of symptoms that subsequently emerge.[12] Classically, CRPS follows fractures, surgery, sprains, contusions, or crush injuries, but it has also been documented after minor procedures such as venipuncture or intravenous line placement, underscoring the fact that even relatively trivial peripheral insults can trigger a profound and sustained pain response.[12][13] In some patients, no clear precipitating injury can be identified, or the syndrome appears after periods of prolonged immobilization, casting, or limb disuse, suggesting that altered neuroimmune and autonomic mechanisms, rather than mechanical damage alone, play a central role in disease pathogenesis.[13] Superimposed psychological distress at the time of injury or during early recovery—such as heightened anxiety, catastrophic thinking, or depressive symptoms—has been proposed to modulate pain perception, coping, and rehabilitation engagement, thereby influencing the clinical course and prognosis, although evidence remains mixed.[14][16] Fractures are among the most frequently reported triggers of CRPS and provide important insight into its development. A large multicenter prospective study demonstrated that nearly half (48.5%) of individuals met IASP criteria for CRPS after sustaining a single fracture of the ankle, wrist, scaphoid, or fifth metatarsal, and symptoms remained persistent in a significant subset at one year.[12] Within this cohort, rheumatoid arthritis, intraarticular ankle fractures, and fracture-dislocations emerged as notable risk factors, indicating that both systemic inflammatory status and local joint involvement may amplify susceptibility.[12] Notably, no major difference was observed between upper and lower limb fractures, suggesting that the regional vulnerability is not limited to a particular extremity. Another cohort study reported that CRPS symptoms typically arise within approximately eight weeks of a noxious event, aligning with the subacute trajectory often observed clinically.[13] While a proportion of patients experience partial or substantial symptom resolution by three months, others continue to meet diagnostic criteria at one year, indicating that early trajectories may diverge into self-limiting versus chronic, refractory disease states.[13]



Fig. 2: Etiology of complex regional pain syndrome.

Distal radius fractures have been a particular focus of etiologic research, with several studies associating older age, psychosocial stressors, and preexisting psychiatric comorbidities—such as depression or anxiety—with a heightened risk of subsequent CRPS.[14][15] These findings support the notion that biological vulnerability intersects with psychological and social factors to shape disease expression. However, other prospective data have not consistently confirmed a direct causal association between psychological variables and CRPS onset, emphasizing that psychological factors are likely modulators rather than primary causes and that individual susceptibility is multifactorial.[16] Surgical procedures, especially those involving the extremities, constitute another well-recognized etiologic category. Postoperative CRPS is frequently reported after fracture fixation, soft-tissue reconstruction, and elective orthopedic interventions. In a retrospective series of 390 patients undergoing foot or ankle surgery, 4.36% developed CRPS, highlighting that operative trauma and postoperative immobilization can initiate or perpetuate the syndrome.[17] Among patients treated for distal radius fractures, those managed with closed reduction and casting exhibited CRPS rates as high as 32.2%, particularly when immobilization was prolonged or complications such as malalignment or stiffness developed.[18] Moreover, carpal tunnel release has been associated with CRPS incidences of approximately 2% to 5%, while surgeries for Dupuytren contracture demonstrate an even wider reported range of 4.5% to 40%, possibly reflecting variability in surgical technique, postoperative rehabilitation, and patient susceptibility.[18] These findings underscore the importance of meticulous perioperative care and early mobilization strategies in high-risk individuals. The contribution of genetic factors to CRPS etiology remains an evolving area of research. Emerging evidence suggests that certain polymorphisms, including human leukocyte antigen (HLA) variants and tumor necrosis factor-alpha (TNF-α)–related genetic markers, may predispose

individuals to earlier onset, greater pain intensity, or more severe disease courses.[19] Retrospective observations of familial clustering and reports of CRPS occurring in multiple members of the same family further support the possibility of heritable susceptibility.[19] Although definitive genetic mechanisms have not yet been established, these data indicate that CRPS likely arises from a complex interplay of peripheral injury, immune and autonomic dysregulation, psychological factors, and genetic predisposition, rather than from any single etiologic pathway.

Epidemiology

The epidemiology of complex regional pain syndrome (CRPS) reveals notable geographic variability, differences in demographic distribution, and diverse clinical patterns influenced by methodological factors, diagnostic criteria, and population characteristics. Early epidemiologic investigations highlighted CRPS as an uncommon but clinically significant chronic pain condition. One of the most frequently cited population-based studies, conducted in Olmsted County, Minnesota, by Sandroni et al. in 2003, reported an incidence of 5.46 cases per 100,000 person-years for CRPS type 1 and 0.82 per 100,000 person-years for type 2, suggesting that CRPS is relatively rare in the United States population when applying the International Association for the Study of Pain (IASP) criteria available at that time.[20] In contrast, a 2006 Dutch study by Mos et al. identified a substantially higher incidence of 26.2 cases per 100,000 person-years, highlighting how incidence rates may differ considerably based on regional awareness, diagnostic practices, referral patterns, and possibly genetic or environmental factors.[21] Both studies demonstrated a pronounced sex predilection, with CRPS occurring more frequently in females. The Minnesota cohort indicated that females were four times more likely than males to develop CRPS, while the Netherlands analysis suggested a threefold female predominance.[20][21] These findings align with broader chronic pain epidemiology research, which consistently documents higher rates of neuropathic and musculoskeletal pain disorders in women. Hormonal influences, immune modulation, and sex-based differences in pain perception and reporting may contribute to this pattern.

Age distribution also varied between the two studies. The Dutch cohort reported a peak incidence between 61 and 70 years, reflecting a higher burden among older adults. Conversely, the Minnesota study reported a median onset age of 46 years, suggesting earlier manifestation within the American population.[20][21] The reasons for these discrepancies remain unclear but may reflect population demographics, patterns of trauma, or differences in healthcare access. Both studies, however, reported greater involvement of the upper extremities, particularly following fractures or surgical procedures. Indeed, fractures were identified as the most common inciting event, accounting for 44% to 46% of all reported cases.[21] Clinical features reported across both studies were consistent with classical CRPS symptomatology. Vasomotor disturbances—including swelling, cutaneous temperature variability, and mottled or erythematous skin discoloration—were among the most frequently observed findings, supporting their diagnostic relevance.[21] Diagnostic approaches also showed convergence: three-phase bone scintigraphy demonstrated utility in approximately 85% of cases, while autonomic testing identified characteristic abnormalities in 80%, reinforcing their value as adjunctive tools when clinical findings are inconclusive.[22] Multiple risk factors have been associated with increased susceptibility to CRPS. Observational studies and retrospective analyses have linked conditions such as asthma, osteoporosis, and menopause with heightened risk, suggesting potential roles for systemic inflammation, hormonal influences, and altered bone metabolism. Use of angiotensin-converting enzyme (ACE) inhibitors, as well as comorbid migraine and cigarette smoking, has also been implicated in elevating risk, possibly through effects on vascular tone, neurogenic inflammation, or peripheral sensitization.[22][23] Collectively, epidemiologic evidence underscores CRPS as a multifactorial pain condition shaped by biological vulnerability, environmental triggers, and population-specific characteristics.

Pathophysiology

Multiple, overlapping pathophysiologic mechanisms have been proposed to explain complex regional pain syndrome (CRPS), and current evidence does not support a single unifying cause. Instead, CRPS is regarded as a multifactorial disorder arising from a dynamic interplay between peripheral and central nervous system sensitization, immune and inflammatory processes, and autonomic dysregulation.[24] These mechanisms appear to be initiated by tissue injury or trauma in most cases, but can also be triggered by minor procedures or even occur without an obvious insult, suggesting that individual susceptibility and neuroimmune vulnerability play significant roles. The relative contribution of each mechanism may vary between patients and even across different disease stages, which partly explains the heterogeneity of clinical presentations and variable responses to treatment.

Inflammatory Changes

Clinical features and laboratory findings strongly support inflammation as a key early driver of CRPS pathophysiology. Patients frequently exhibit the cardinal signs of inflammation—warmth, swelling, erythema, pain, and functional impairment—in the affected region, particularly in the so-called “warm” phase of the disorder.[24] Biochemically, elevated levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha

(TNF-α) and interleukins 1β, 2, and 6, have been detected in both serum and cerebrospinal fluid, indicating systemic as well as central inflammatory activation.[25][26][27][28] In addition, neuropeptides such as calcitonin gene–related peptide (CGRP), bradykinin, and substance P are released from peripheral nociceptive endings following tissue injury and contribute to neurogenic inflammation.[29][30] These mediators promote vasodilation, increased vascular permeability, and plasma extravasation, leading to edema, temperature asymmetry, and color changes characteristic of CRPS.[29][31][32] The persistence of elevated cytokines and neuropeptides may drive chronic inflammatory signaling, sensitize nociceptors, and set the stage for ongoing pain long after the initial tissue insult has resolved.

Immunological Changes

Accumulating evidence suggests that autoimmune mechanisms also contribute to CRPS pathogenesis. Autoantibodies directed against G-protein–coupled receptors, including β2-adrenergic, α1a-adrenergic, and muscarinic M2 receptors, have been identified in subsets of patients with CRPS.[33][34] These antibodies may alter autonomic and nociceptive signaling by functionally modulating receptor activity on vascular, immune, and neural cells, thereby reinforcing both pain and dysautonomia. Clinical observations further support an immune-mediated component: Goebel et al. reported significant improvements in pain following intravenous immunoglobulin (IVIG) administration in patients with refractory CRPS, implying that antibody neutralization or immunomodulation can ameliorate symptoms in at least some cases.[35] Although these data are not yet definitive and CRPS is not classically categorized as an autoimmune disease, they highlight the potential role of adaptive immunity in disease maintenance and severity.

Peripheral Sensitization

Peripheral sensitization is thought to arise when inflammatory and neurogenic mediators lower the activation threshold of nociceptors in the injured region, rendering previously non-painful stimuli painful and amplifying responses to noxious inputs.[24][29] TNF-α and related pro-inflammatory cytokines directly modulate ion channels and receptors on primary afferent fibers, increasing excitability and spontaneous firing.[25][27] In CRPS, this localized hyperexcitability contributes to primary hyperalgesia and mechanical allodynia within the affected limb. Furthermore, altered catecholamine sensitivity of peripheral nerve fibers has been demonstrated, suggesting that sympathetic neurotransmitters such as norepinephrine can aberrantly activate or sensitize nociceptors. This phenomenon may partially explain why emotional stress or sympathetic arousal can exacerbate pain in some patients and supports the concept of sympathetically maintained pain in certain CRPS phenotypes.



Fig. 3: Pathophysiology of complex regional pain syndrome.

Central Sensitization and Neuroplasticity

Persistent nociceptive input from sensitized peripheral afferents can induce profound changes within the central nervous system. In CRPS, increased excitability of second-order neurons in the dorsal horn of the spinal cord has been demonstrated, leading to central sensitization.[36] This state is characterized by expansion of receptive fields, heightened responses to stimuli, and pain elicited by normally innocuous inputs (allodynia). Neurochemical mediators such as substance P, bradykinin, and glutamate play important roles in this process, with repetitive noxious input producing "wind-up" phenomena and sustained activation of N-methyl-D-aspartate (NMDA) receptors.[36][37] The clinical efficacy of ketamine, an NMDA receptor antagonist, in some CRPS patients supports the central role of NMDA-dependent mechanisms in maintaining central sensitization.[36][37] Inhibitory pathways also appear to be disrupted. Improvement of CRPS symptoms with intrathecal baclofen, a gamma-aminobutyric acid (GABA) agonist, suggests that impaired GABAergic inhibition contributes to the imbalance between excitatory and inhibitory signaling in the spinal cord and supraspinal centers.[36] At the cortical level, functional imaging

and neurophysiologic studies have revealed reorganization within the primary somatosensory cortex, including a reduction in the cortical representation area corresponding to the affected limb.[38] The extent of such cortical reorganization correlates with pain intensity and severity of hyperalgesia, indicating that maladaptive neuroplasticity is both a consequence and a driver of chronic pain in CRPS.[39][40] These central changes help explain why symptoms can spread beyond the original site of injury and why purely peripheral interventions may fail to achieve complete remission in longstanding disease.

Autonomic Changes

Autonomic dysregulation is a hallmark feature of CRPS and is closely tied to both pain generation and the characteristic vasomotor and sudomotor abnormalities.[41] Sympathetic-afferent coupling is believed to occur when upregulation of adrenergic receptors on nociceptive fibers renders them responsive to sympathetic outflow. As a result, sympathetic hyperactivity—whether due to stress, temperature changes, or orthostatic shifts—can exacerbate pain and perpetuate a vicious cycle of nociception and dysautonomia.[41] Clinically, this manifests as fluctuating skin temperature, color changes, abnormal sweating, and localized swelling. Beyond the affected limb, evidence of widespread autonomic instability has been reported, including alterations in heart rate variability and orthostatic intolerance, suggesting that systemic autonomic control is also impaired.[42] Phenotypic distinctions between “warm” and “cold” CRPS may reflect different patterns of autonomic imbalance. In warm CRPS, early vasodilation and increased blood flow appear to result from reduced peripheral catecholamine release or receptor responsiveness, whereas in cold CRPS, later-stage vasoconstriction predominates, likely driven by heightened sympathetic activity or receptor sensitivity.[41][42] These autonomic shifts not only contribute to pain and trophic changes but may also influence tissue oxygenation, bone metabolism, and long-term limb viability, further underscoring the complex and integrated nature of CRPS pathophysiology.

History and Physical

Patients with complex regional pain syndrome (CRPS) typically present with a constellation of sensory, motor, and autonomic disturbances that evolve over time and often follow a precipitating injury or surgery. Sensory symptoms are central to the clinical picture and frequently include allodynia, in which normally nonpainful stimuli such as light touch, clothing, or gentle movement provoke intense pain, and hyperalgesia, where stimuli that are usually painful elicit exaggerated or disproportionately severe pain responses.[43] These sensory changes are usually regional rather than focal, often involving the distal aspect of a limb and extending beyond the territory of any single peripheral nerve or dermatome. Patients may describe burning, throbbing, or stabbing pain that is continuous or fluctuating, and often worsens with activity, emotional stress, or temperature changes.[43] Autonomic symptoms reflect vasomotor and sudomotor dysfunction. Clinically, this may manifest as alterations in skin temperature—warmer or cooler than the contralateral limb—as well as mottling, erythema, or cyanosis of the skin.[43] Episodes of increased or decreased sweating, sometimes limited to the affected area, further support the diagnosis. Edema is common, particularly in early stages, and may be exacerbated by dependent positioning or immobility. Motor manifestations are also frequent and can be striking. Patients may exhibit weakness, stiffness, and a reduced range of motion due to pain, soft-tissue changes, or joint contractures. Tremor and muscle spasms are not uncommon, and in more severe cases, fixed dystonic postures of the fingers, wrist, ankle, or toes may develop, further impairing function and complicating rehabilitation.[43] CRPS has profound psychological and functional consequences. Depression, anxiety, irritability, and sleep disturbances often emerge or worsen as pain persists and functional abilities decline. A systematic review by Lohnberg et al found no robust evidence that specific personality traits or preexisting psychopathologies predict the development of CRPS; however, individuals with significant psychological comorbidities or limited coping resources may exhibit more pronounced pain behaviors, avoidance of movement, and catastrophic thinking, which can perpetuate disability and hinder recovery.[44] Reduced participation in work, family roles, and social activities contributes to a downward spiral of isolation, deconditioning, and loss of self-efficacy, making early psychological assessment and support essential.[44][45]

Beyond localized limb findings, CRPS has been associated with a range of systemic medical complications. Neuropsychological disturbances, including deficits in executive function, memory, attention, and word retrieval, have been reported and may reflect chronic pain, sleep deprivation, mood disturbance, or medication effects.[45] Many patients describe constitutional symptoms such as fatigue, generalized weakness, and nonrestorative sleep, which further erode quality of life.[45][46] Cardiopulmonary manifestations, including neurocardiogenic syncope, palpitations, atypical chest pain, and chest wall muscle dystonia leading to dyspnea, suggest broader autonomic instability beyond the affected limb.[46] Endocrine disturbances have also been observed, including dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis with low serum cortisol levels and associations with hypothyroidism, raising the possibility that chronic stress and neuroendocrine imbalance contribute to symptom persistence.[47] Urologic symptoms such as urinary urgency, frequency, or incontinence, and

gastrointestinal dysmotility presenting as nausea, vomiting, diarrhea, constipation, or indigestion, further highlight the systemic impact of autonomic dysfunction in CRPS.[48] Taken together, the history and physical examination in CRPS must extend beyond regional limb findings to encompass psychological status and multisystem manifestations, enabling a comprehensive, biopsychosocial assessment that guides multidisciplinary management.

Evaluation

Because no single, definitive pathophysiologic mechanism has been identified for complex regional pain syndrome (CRPS), there is no gold-standard diagnostic test. Instead, diagnosis relies primarily on clinical assessment, structured history-taking, and a focused physical examination. The most widely accepted diagnostic framework is the Budapest Criteria, which were developed to improve diagnostic accuracy over the earlier International Association for the Study of Pain (IASP) criteria. Although both systems demonstrate excellent sensitivity, the Budapest Criteria offer substantially improved specificity (0.68 versus 0.36–0.50), reducing diagnostic overreach while maintaining the ability to identify true cases.[24] The Budapest Criteria require fulfillment of *all four* components. First, the patient must report persistent regional pain that is disproportionate to the inciting event—often trauma, surgery, or immobilization. This pain is typically described as burning, shooting, or deep aching, and presents without conformity to a dermatomal or peripheral nerve distribution. Second, the patient must report symptoms in at least three of the following four categories: sensory (hyperalgesia or allodynia), vasomotor (color or temperature asymmetry), sudomotor/edema (abnormal sweating or swelling), and motor/trophic (reduced range of motion, weakness, tremor, dystonia, or trophic changes). Third, during examination, the clinician must observe at least one objective sign in two or more of these same categories, such as pinprick hyperalgesia, overt temperature asymmetry, noticeable edema, or visible trophic skin, hair, or nail changes. Fourth, no alternative diagnosis should better explain the clinical picture. This criterion reinforces CRPS as a diagnosis of exclusion, underscoring the necessity of careful differential consideration.

While CRPS remains fundamentally a clinical diagnosis, ancillary testing may support evaluation or help rule out competing conditions. Tests such as thermography can document temperature asymmetry; triple-phase bone scintigraphy may demonstrate periarticular increased uptake, especially in early disease; and quantitative sudomotor axon reflex testing (QSART) can identify sudomotor abnormalities consistent with autonomic dysfunction. Nonetheless, none of these tests possess sufficient sensitivity or specificity to serve as mandatory diagnostic tools, and their findings must always be interpreted within the broader clinical context. Because CRPS shares features with many other conditions, it is essential to exclude alternative diagnoses. Potential mimics include small-fiber neuropathy, large-fiber neuropathy, cellulitis, erythromelalgia, vasculitis, vascular insufficiency, lymphedema, deep vein thrombosis, and Raynaud phenomenon. These disorders may present with some combination of pain, edema, skin color changes, or autonomic signs, necessitating targeted laboratory testing and appropriate imaging to differentiate them from CRPS. For example, duplex ultrasonography may be required to exclude deep vein thrombosis, while vascular studies may help clarify ischemic etiologies. Ultimately, CRPS diagnosis rests on the clinician's ability to integrate patient history, physical findings, and exclusion of mimicking conditions. Accurate diagnosis is critical, as early identification improves prognosis and enables prompt initiation of multimodal treatment strategies aimed at mitigating chronicity, functional decline, and long-term disability.

Treatment / Management

Although spontaneous improvement is documented in a subset of individuals with complex regional pain syndrome (CRPS), early, proactive, and aggressive intervention is strongly recommended given the syndrome's profound impact on pain, function, and quality of life.[49] Delayed or fragmented treatment is consistently associated with poorer functional recovery, greater risk of chronic disability, and entrenched central sensitization, whereas early-stage CRPS tends to be more amenable to multimodal therapy and carries a more favorable prognosis.[49] The principal therapeutic goals are to alleviate pain, restore and preserve function, prevent secondary complications such as contractures and disuse atrophy, and address psychological distress. Achieving these aims requires a coordinated interprofessional strategy integrating physical and occupational therapy, pharmacological management, behavioral interventions, and, when indicated, interventional or neuromodulatory procedures. Physical and occupational therapy form the cornerstone of CRPS management, often serving as the primary modality around which other treatments are organized. Beyond conventional therapeutic exercise and joint mobilization, a wide array of adjunctive techniques has been applied, including transcutaneous electrical nerve stimulation, therapeutic ultrasound, laser therapy, structured pain education, mirror therapy, and graded motor imagery.[50] Manual therapy and active exercise are believed to improve range of motion, limb use, and overall function while reducing disability through mechanisms that include endorphin release and modulation of both central and peripheral nociceptive

processing.[50] Pain neuroscience education helps patients reconceptualize pain as a modifiable neurophysiological process rather than a direct indicator of ongoing tissue harm, thereby reducing fear-avoidance behaviors and facilitating engagement with rehabilitation. Mirror therapy and graded motor imagery explicitly target maladaptive cortical reorganization and central sensitization, phenomena implicated in CRPS-related chronic pain and motor impairment.[51]

Evidence for these modalities, although promising, remains of variable quality. A 2016 Cochrane review suggested that mirror therapy and graded motor imagery can improve both pain intensity and functional outcomes in CRPS, with two clinical trials demonstrating clinically meaningful improvements at six months.[51] However, the overall quality of evidence was limited, and sample sizes were small, leading to cautious interpretation. The same review reported very low-quality evidence that multimodal physiotherapy, incorporating exercise and desensitization techniques, may reduce impairment in some patients. An updated Cochrane review in 2022, incorporating 16 additional trials, further supported the potential benefit of multimodal physiotherapy, aerobic exercise, graded motor imagery, mirror therapy, virtual reality interventions, transcutaneous electrical nerve stimulation, and exposure-in-vivo protocols in reducing pain or disability in type 1 CRPS, though most beneficial effects were short term and the certainty of evidence remained low to moderate.[52] Consequently, physical and occupational therapy are regarded as essential first-line treatments, even as research continues to refine optimal protocols and dosing. Pharmacotherapy is typically employed alongside rehabilitation to attenuate pain, modulate neuroinflammation, and support functional progress. A multimodal regimen is often favored, combining several drug classes tailored to individual symptom profiles. Commonly used agents include nonsteroidal anti-inflammatory drugs and corticosteroids, anticonvulsants, antidepressants, topical lidocaine, opioids in carefully selected cases, N-methyl-D-aspartate (NMDA) receptor antagonists, and bisphosphonates.[53][57] Anti-inflammatory medications are rational choices given the documented inflammatory milieu in CRPS. A 2013 Cochrane review analyzing three trials comparing oral corticosteroids with placebo found no statistically significant reduction in pain intensity; however, steroids did appear to improve composite CRPS scores that incorporated pain, edema, and range of motion, albeit based on very low-quality evidence.[53] Subsequent work in poststroke CRPS demonstrated that oral prednisone was superior to the NSAID piroxicam in improving composite CRPS outcomes, and a more recent study confirmed that a two-month course of low-dose prednisone was both safe and effective in this population.[54][55] Reflecting these data, 2022 CRPS guidelines recommend considering an early short course of oral corticosteroids, typically 30 mg daily for 2 to 12 weeks followed by tapering, while acknowledging the limitations and methodological weaknesses of the underlying trials.[56]

Bisphosphonates, which inhibit osteoclastic bone resorption, have also garnered attention. Their mechanisms in CRPS may extend beyond bone metabolism to include modulation of inflammatory responses and suppression of bone marrow cell activity.[57] A 2017 meta-analysis concluded that bisphosphonates, such as alendronate or pamidronate, appear to reduce pain in patients with type 1 CRPS, especially in those demonstrating osteopenia or osteoporosis on imaging.[58] Similarly, a 2013 Cochrane review suggested low-quality evidence supporting bisphosphonate efficacy, again particularly in patients with concomitant bone density loss.[58] Given their risk–benefit profile, bisphosphonates are considered a reasonable option in selected cases, especially where structural bone involvement and severe pain coexist. Among neuromodulatory pharmacologic agents, gabapentin is the most extensively studied anticonvulsant in CRPS. It acts by binding to the α2δ subunit of voltage-gated calcium channels, thereby reducing excitatory neurotransmitter release. Despite its frequent use, evidence for gabapentin in type 1 CRPS remains weak, with very low-quality data suggesting limited effectiveness.[59] A 2016 clinical study comparing gabapentin with the tricyclic antidepressant amitriptyline in adults with type 1 CRPS and children with neuropathic pain showed that both drugs significantly reduced pain intensity and disability, with no clear superiority of one over the other.[59] These findings support the use of gabapentin and tricyclic antidepressants as viable options within a broader multimodal regimen, particularly in patients with neuropathic pain features and sleep disturbance. The role of opioids remains less certain; given the risk of tolerance, dependence, and adverse effects, opioids are generally reserved for short-term symptom control in refractory cases and should be embedded within a comprehensive, time-limited plan emphasizing functional goals.



Fig. 4: Mechanism based treatment of complex regional pain syndrome.

NMDA receptor antagonists such as ketamine have attracted interest due to their potential

to reverse central sensitization and maladaptive plasticity. Low-quality studies indicate that intravenous ketamine infusions can produce clinically significant pain relief lasting from four to eleven weeks in some individuals with CRPS.[36][37][60] However, side effects, including psychomimetic experiences, cardiovascular changes, and hepatotoxicity with repeated dosing, have constrained its widespread adoption. Data on magnesium, another NMDA antagonist, are less robust. A 2024 systematic review and meta-analysis identified two relevant studies: a 2009 trial in 10 patients reporting pain attenuation with an intravenous magnesium dose of 70 mg/kg, and a 2013 trial in 56 patients that failed to replicate these benefits at the same dosage.[60] These conflicting findings highlight the need for larger, methodologically rigorous trials before magnesium can be routinely recommended for CRPS. Given the growing recognition of immune contributions to CRPS, various immunotherapeutic strategies have been explored. A narrative review described the use of interleukin-1 receptor antagonists, glucocorticoids, intravenous immunoglobulin (IVIG), and tumor necrosis factor-alpha inhibitors as potential options in selected patients.[61] Small case series and pilot trials suggest that IVIG and TNF-α blockers may confer benefit in some refractory CRPS cases, particularly where autoantibody-mediated mechanisms are suspected. Nonetheless, these interventions carry substantial costs, immunosuppressive risks, and an incomplete evidentiary base, necessitating cautious, individualized consideration and typically limiting their use to specialist centers or research settings.[35][61]

Behavioral therapy is an important, though historically underinvestigated, component of CRPS management. Elevated catecholamine levels associated with depression and chronic stress can exacerbate central sensitization and pain perception through adrenergic pathways.[62] Psychotherapeutic interventions, including cognitive–behavioral therapy, pain coping skills training, and stress reduction techniques, aim to mitigate these effects by addressing maladaptive thoughts, fear-avoidance behaviors, and catastrophizing while enhancing self-efficacy and adherence to physical rehabilitation. Although only one small clinical trial and a handful of case reports have systematically examined behavioral interventions specifically in CRPS, expert consensus supports their integration into multidisciplinary treatment given the strong bidirectional links between pain and psychological status.[62] In practice, behavioral therapy is most effective when coordinated with physical therapy and pharmacologic measures, rather than pursued in isolation. Procedural interventions are generally reserved for patients whose symptoms remain functionally disabling despite optimized conservative management. Sympathetic nerve blocks are among the most frequently used procedures, based on the concept that sympathetic overactivity and sympathetic–afferent coupling contribute to pain in some CRPS phenotypes.[41] Lumbar sympathetic blocks are typically employed for lower-limb symptoms, while stellate ganglion blocks target upper-extremity involvement. Despite their widespread use, evidence from a 2013 Cochrane review indicated that sympathetic blocks with local anesthetics did not significantly or consistently reduce pain compared with controls, with the certainty of evidence rated as low.[63] A subsequent 2016 review similarly found insufficient robust data to draw definitive conclusions regarding efficacy, suggesting that sympathetic blocks may be useful as diagnostic tools or as part of an individualized regimen rather than as universally effective treatments.

Neuromodulation, particularly spinal cord stimulation (SCS), has emerged as a key interventional option for chronic, refractory CRPS. SCS involves the implantation of epidural electrodes over the dorsal columns of the spinal cord connected to a pulse generator. Mechanisms are multifactorial and may include inhibition of nociceptive transmission, modulation of sympathetic activity, promotion of vasodilation, and reversal of maladaptive cortical changes associated with chronic pain.[63] A 2017 systematic review concluded that SCS provides significant improvements in pain intensity, quality of life, and overall pain relief in many patients with CRPS, especially when implemented after failure of less invasive treatments.[63] Although SCS carries risks such as lead migration, infection, and hardware malfunction, careful patient selection, trial stimulation, and multidisciplinary follow-up can optimize outcomes. Dorsal root ganglion (DRG) stimulation represents a more targeted neuromodulatory technique, delivering electrical stimulation directly to the sensory cell bodies in the dorsal root ganglia corresponding to the affected dermatomes. Approved by the U.S. Food and Drug Administration in 2016 for lower-extremity CRPS, DRG stimulation has demonstrated promising results. A pooled analysis reported a mean 4.9-point reduction in pain scores in type 1 CRPS patients, with favorable safety and tolerability profiles.[64] The landmark ACCURATE trial—a randomized, multicenter study comparing DRG stimulation with traditional SCS in 152 patients with CRPS and causalgia—showed that DRG stimulation achieved superior pain relief, higher rates of treatment success, and improved quality-of-life measures.[65] These findings suggest that DRG stimulation may be particularly valuable for focal, anatomically circumscribed pain and support its growing role as a preferred neuromodulatory option in select CRPS populations. In summary, the management of CRPS demands early recognition and a comprehensive,

multimodal strategy that integrates physical and occupational therapy, individualized pharmacotherapy, psychological support, and selected interventional techniques. While evidence quality varies across modalities, converging data underscore that timely, coordinated care delivered by an interprofessional team offers the best opportunity to reduce pain, restore function, and prevent long-term disability in this complex and often life-altering syndrome.[49][50][52][58][63][65]

Differential Diagnosis

Given the broad, heterogeneous, and often ambiguous clinical presentation of complex regional pain syndrome (CRPS), a careful and systematic differential diagnosis is essential to avoid misclassification and inappropriate treatment. CRPS can mimic, or be mimicked by, several neurological, vascular, rheumatologic, and functional conditions that share overlapping sensory, motor, and autonomic features. Thorough history taking, meticulous physical examination, and targeted diagnostic testing are therefore crucial elements of the evaluation process. Vascular disorders such as arterial insufficiency and peripheral arterial disease may present with limb pain, color changes, temperature asymmetry, and trophic alterations resembling CRPS. However, these typically follow a vascular distribution, are often associated with exertional claudication or rest pain, and can be distinguished by abnormal ankle–brachial indices, Doppler ultrasound, or angiographic findings. Deep vein thrombosis (phlebothrombosis) may likewise produce unilateral swelling, warmth, and pain but is usually accompanied by risk factors such as immobility, recent surgery, or hypercoagulability; duplex venous ultrasonography is indispensable for excluding this potentially life-threatening condition. Vasculitic processes and Raynaud-like phenomena can also cause discoloration and temperature changes, but they tend to follow systemic or acral patterns rather than the regional, nondermatomal distribution typical of CRPS.

Neurological disorders constitute another key category of differential diagnoses. Guillain-Barré syndrome can present with pain, dysesthesias, and autonomic instability but usually manifests as a symmetric ascending polyneuropathy with areflexia rather than a localized limb syndrome. Monomelic amyotrophy, poliomyelitis, and tabes dorsalis may cause weakness, atrophy, or sensory impairment; however, they are associated with distinct neuroanatomical patterns, objective electrophysiologic abnormalities, or specific serologic markers. Multiple sclerosis may produce neuropathic pain, motor deficits, and dysautonomia, yet demyelinating lesions on MRI and multifocal central nervous system involvement help distinguish it from CRPS. Porphyrias occasionally present with neuropathic pain and autonomic dysfunction, but they are typically accompanied by abdominal pain, neuropsychiatric symptoms, and characteristic biochemical abnormalities. Functional and psychiatric conditions, such as conversion disorder (formerly termed hysteria), can mimic CRPS through dramatic motor or sensory symptoms without proportional organic findings. However, while psychogenic contributions are recognized in CRPS, the presence of objective signs—such as edema, color change, sweating abnormalities, temperature asymmetry, and trophic alterations—supports a genuine neurobiologic basis rather than a purely functional etiology. Ultimately, CRPS remains a diagnosis of exclusion, and accurate diagnosis hinges on systematically ruling out these mimicking disorders through appropriate imaging, vascular studies, electrophysiologic testing, and laboratory evaluation, thereby ensuring that patients receive timely, targeted management tailored to the true underlying condition.

Pertinent Studies and Ongoing Trials

Recent research has increasingly focused on elucidating the immunological, biochemical, and molecular underpinnings of CRPS, but high-quality evidence remains limited. Zalewski et al conducted a critical review of clinical research published between 2018 and 2024, specifically analyzing studies investigating immunologic and molecular mechanisms as well as potential targeted therapies.[66] Their analysis revealed substantial methodological heterogeneity across studies, including variability in diagnostic criteria (sometimes inconsistent use of the Budapest criteria), small sample sizes, poorly defined control groups, and short follow-up periods. These limitations hinder the ability to synthesize data quantitatively and draw robust conclusions regarding pathophysiology or treatment efficacy. In light of these challenges, Zalewski et al proposed a strategic reorientation of CRPS research priorities.[66] Rather than emphasizing large, heterogeneous cohorts with broad inclusion criteria, they advocate for smaller but methodologically rigorous studies, carefully characterized case series, and n-of-1 trials, recognizing that CRPS is both rare and clinically diverse. They emphasize the necessity of strict adherence to Budapest clinical or research criteria, with clear designation of which version is used, to ensure diagnostic consistency and facilitate comparability across studies. Furthermore, they recommend that experimental designs enroll at least 30 participants where it is feasible to achieve adequate statistical power while still maintaining a detailed phenotypic characterization of each case. Given ethical concerns around withholding treatment or exposing patients with severe pain to prolonged placebo conditions, Zalewski et al argue for prioritizing comparative effectiveness trials—comparing active treatments, combination regimens, or stepped-care models—over placebo-controlled randomized controlled trials in many

circumstances.[66] They also stress the importance of extended follow-up, recommending a minimum duration of 24 months to adequately capture long-term outcomes, response durability, and late-emerging adverse effects. Additionally, the authors highlight the need for comprehensive and reproducible outcome measures that reflect the multidimensional nature of CRPS.[66] They propose that future studies should assess not only pain intensity but also functional disability, anxiety and depressive symptoms, quality of life, sleep quality, kinesiophobia (fear of movement), and cognitive function. Such a multidomain outcome set would better capture the full burden of CRPS and provide a more meaningful assessment of treatment benefits. This evolving research agenda aims to generate more nuanced, clinically applicable evidence to guide personalized therapeutics in CRPS and to eventually identify biologically informed subtypes that may respond preferentially to specific interventions.

Staging

Historically, attempts have been made to stage CRPS along a temporal or clinical continuum. In 1990, Bonica proposed a three-stage model describing an initial acute or "warm" inflammatory phase, followed by a dystrophic stage characterized by edema, trophic changes, and emerging stiffness, and eventually an atrophic stage associated with cold, cyanotic skin, severe contractures, and functional loss.[67] This model was conceptually appealing because it resonated with clinical observations of changing symptom patterns over time, and it provided a framework for prognostication and treatment selection. Early stages were thought to be more responsive to intervention, while late-stage disease was presumed to be largely irreversible. However, subsequent empirical research has cast doubt on the validity and universal applicability of such discrete staging. Bruehl et al investigated this issue in a cohort of 113 patients diagnosed with CRPS and systematically assessed symptom patterns, disease duration, and functional status.[67] Their findings revealed no consistent or statistically significant association between symptom duration and the presence of "stage-specific" clinical features as defined by Bonica's model. Patients with long-standing CRPS could still present with primarily inflammatory signs such as warmth and edema, while others with relatively recent onset already exhibited pronounced atrophic changes. This variability suggested that the proposed stages did not represent a uniform, linear progression that applies to all patients. As a result, the notion of rigid, generalized staging in CRPS is now viewed with skepticism. Instead, contemporary understanding emphasizes that CRPS manifestations exist along overlapping spectrums—such as warm versus cold phenotypes, degree of central sensitization, and relative contributions of inflammatory, autonomic, and psychological factors—rather than discrete, time-bound stages.[8][67] Clinically, this means that treatment decisions should be guided by the current symptom profile, functional impairments, and individualized risk factors rather than by presumed stage based solely on disease duration. Nevertheless, the concept of early versus late presentation retains prognostic relevance, as early recognition and intervention remain associated with better outcomes, even if distinct stages cannot be reliably delineated in all cases.

Prognosis

The prognosis of CRPS is highly variable and depends on numerous factors, including the timeliness of diagnosis, the adequacy of early management, the nature of the inciting event, comorbid psychological and medical conditions, and the degree of central sensitization and functional impairment at presentation.[49] Outcomes range from complete or near-complete remission to chronic, severely disabling disease that persists for years or even decades. While spontaneous improvement can occur, particularly in milder cases or in those recognized early, many patients require sustained, multidisciplinary management to achieve acceptable levels of pain control and function. Evidence suggests that early intervention significantly improves prognosis by interrupting the progression of peripheral and central sensitization, preventing contractures and disuse atrophy, and mitigating psychological distress. Patients enrolled in treatment programs soon after symptom onset tend to demonstrate greater functional gains, reduced pain intensity, and lower rates of long-term disability than those with delayed diagnosis or fragmented care.[49] Conversely, prolonged disease duration, extensive trophic changes, entrenched dystonia, and significant cortical reorganization are associated with poorer outcomes and limited reversibility, even with aggressive therapy. Psychosocial factors play an important role in prognosis. Comorbid depression, anxiety, pain catastrophizing, fear of movement, and maladaptive coping strategies can amplify pain perception, diminish engagement in rehabilitation, and prolong disability. Addressing these factors through cognitive–behavioral therapy, pain education, and supportive counseling can improve treatment adherence and functional recovery, highlighting the importance of integrated behavioral health care.[9][10][11] Additionally, systemic comorbidities such as autoimmune disease, osteoporosis, or endocrine dysfunction may further complicate management and contribute to symptom persistence. Although robust long-term epidemiologic data remain limited, available studies suggest that a substantial proportion of patients continue to experience some degree of pain, stiffness, or functional limitation years after onset, even when overall improvement occurs.[52][63] Nevertheless,

with timely, individualized, and multidisciplinary treatment—including early physical and occupational therapy, tailored pharmacotherapy, and, when needed, neuromodulation—many patients achieve meaningful reductions in pain and substantial improvements in quality of life. Therefore, while CRPS can be a chronic and refractory condition, early recognition and proactive, comprehensive care substantially modulate its trajectory and prognosis.

Complications

CRPS is increasingly recognized as a systemic disorder with potential multi-organ involvement rather than a purely localized pain syndrome. Chronic, inadequately controlled CRPS can give rise to numerous complications that extend beyond the musculoskeletal and peripheral nervous systems. Among the most disabling are movement disorders, particularly dystonia, which may manifest as sustained, involuntary muscle contractions resulting in abnormal postures of the hand, wrist, foot, or ankle. These dystonic postures can severely impair function, hinder rehabilitation, and predispose to contractures and secondary joint damage. Tremor, myoclonus, and fixed flexion deformities may also occur, complicating daily activities and caregiving. Cognitive and neuropsychological complications have been reported, including deficits in executive function, attention, memory, and word retrieval.[45] These may reflect a combination of chronic pain, sleep disruption, medication side effects, mood disorders, and possible central nervous system changes associated with persistent nociceptive input and neuroinflammation. Such cognitive impairments can further compromise occupational functioning, social participation, and adherence to complex treatment regimens. CRPS may also affect the endocrine system. Dysregulation of the hypothalamic–pituitary–adrenal axis has been described, including evidence of adrenal insufficiency and low serum cortisol in some patients, which may manifest as fatigue, hypotension, and reduced stress tolerance.[47] Thyroid dysfunction, particularly hypothyroidism, has likewise been associated with CRPS, though causal links remain incompletely defined. Gastrointestinal dysmotility, including gastroparesis, constipation, diarrhea, abdominal discomfort, and symptoms resembling irritable bowel syndrome, suggests autonomic involvement of the enteric nervous system.[48] These GI symptoms can significantly impact nutrition, energy levels, and overall well-being. Additional complications include cardiopulmonary manifestations such as neurocardiogenic syncope, atypical chest pain, palpitations, and chest wall muscle dystonia resulting in dyspnea or impaired respiratory mechanics.[46] Urological disturbances—such as urinary urgency, frequency, nocturia, and incontinence—further underscore the widespread autonomic dysregulation observed in some patients.[48] Collectively, these complications emphasize that CRPS may evolve into a complex chronic illness with systemic consequences, necessitating an interprofessional approach that includes neurology, pain medicine, endocrinology, gastroenterology, psychiatry, and rehabilitation subspecialties to address the full spectrum of patient needs and minimize long-term morbidity.

Patient Education

Prevention and patient education are key components of CRPS management, especially in individuals at increased risk following fractures, surgery, or immobilization. Oral vitamin C has been proposed as a simple, low-cost preventive strategy based on its antioxidant properties and potential ability to modulate free radical–mediated tissue damage and neuroinflammation. A 2015 meta-analysis that pooled data from three clinical trials assessing vitamin C after distal radius fractures concluded that existing evidence did not definitively support its efficacy in preventing CRPS, and the overall quality of evidence was rated as low.[68] Methodologic limitations, including small sample sizes, variable dosing regimens, and inconsistent outcome measures, tempered the conclusions of this analysis. In contrast, a 2017 systematic review and meta-analysis focusing on wrist fractures reported that administering 500 mg of vitamin C daily for 50 days after injury significantly reduced the incidence of CRPS one year later.[69] These findings suggest a potential protective effect of vitamin C in selected populations, although questions remain regarding optimal dose, duration, and generalizability to other types of limb injuries or surgeries. Given its favorable safety profile, low cost, and biologic plausibility, some clinicians incorporate vitamin C prophylaxis into postoperative or post-fracture regimens, particularly in high-risk patients, while acknowledging that more rigorous, large-scale trials are needed to definitively establish its preventive role.[68][69] Beyond pharmacologic deterrence, comprehensive patient education is essential. Patients should be informed about early warning signs of CRPS—such as disproportionate pain, persistent swelling, temperature or color changes, and hypersensitivity—so that they can seek prompt medical evaluation if symptoms arise after injury or surgery. Education should emphasize the importance of early mobilization within safe limits, adherence to physical therapy, and avoidance of prolonged immobilization when not medically necessary. Clear communication about expectations, treatment goals, and the biopsychosocial nature of pain can reduce fear, enhance engagement in rehabilitation, and mitigate maladaptive avoidance behaviors. Involving patients and families as active partners in care fosters self-management skills and may reduce the risk of CRPS chronicity and associated disability.

Enhancing Healthcare Team Outcomes

Effective management of CRPS requires a tightly coordinated interprofessional team, as the condition encompasses complex interactions among sensory, motor, autonomic, psychological, and social domains. Fragmented or unidimensional care often leads to suboptimal outcomes, whereas integrated, team-based approaches can optimize recovery trajectories and reduce long-term disability. Early involvement of multiple disciplines allows for comprehensive assessment and the creation of a unified, patient-centered treatment plan that can be adjusted over time as needs evolve. Key members of the interprofessional team include physicians (such as pain specialists, neurologists, physiatrists, anesthesiologists, and primary care providers), nurses, physical and occupational therapists, psychologists or psychiatrists, pharmacists, and social workers. Nurses play a central role in ongoing symptom assessment, patient education, monitoring of treatment responses, and coordination of care transitions. Physical and occupational therapists design and implement individualized rehabilitation programs that focus on graded activity, desensitization, motor retraining, and functional restoration, providing continuous feedback to the broader team about progress and barriers. Pharmacists contribute expertise in optimizing polypharmacy, identifying potential drug–drug interactions, managing side effects, and educating patients about proper medication use and tapering strategies. Mental health professionals address depression, anxiety, trauma-related symptoms, maladaptive pain beliefs, and coping deficits through cognitive–behavioral therapy, pain coping skills training, and, when needed, pharmacologic interventions. Social workers assist with psychosocial support, disability and workplace issues, financial and insurance navigation, and linkage to community resources, which is particularly important in chronic, disabling conditions. Early referral to pain management specialists is crucial when first-line measures do not adequately control symptoms, allowing timely consideration of interventional procedures such as sympathetic blocks, spinal cord stimulation, or dorsal root ganglion stimulation.[63][65] Regular interdisciplinary meetings, shared documentation, and clear communication channels ensure that all providers remain aligned on treatment goals, avoid duplicative or conflicting therapies, and can rapidly respond to changes in the patient's condition. Such collaborative, coordinated care models not only enhance clinical outcomes but also improve patient satisfaction and provider efficiency, ultimately fostering a more sustainable and compassionate approach to managing this challenging and complex pain syndrome.

Conclusion:

In conclusion, Complex Regional Pain Syndrome (CRPS) is a severe and multifaceted chronic pain disorder whose management demands an integrated, proactive, and interprofessional approach. No single treatment is universally effective, underscoring the necessity of a multimodal strategy tailored to the individual patient. The cornerstone of care involves early and aggressive physical and occupational therapy to combat disuse and restore function, combined with pharmacological interventions to modulate pain and inflammation. Critically, psychological support must be integrated to address the profound mood disturbances, fear-avoidance behaviors, and catastrophizing that often perpetuate the pain cycle and hinder recovery. For patients with refractory symptoms, interventional procedures such as spinal cord or dorsal root ganglion stimulation offer promising avenues for significant pain relief and functional improvement. Ultimately, successful outcomes depend on a coordinated team effort involving physicians, nurses, physical and occupational therapists, psychologists, and pharmacists. This collaborative model ensures that all dimensions of the syndrome—sensory, motor, autonomic, and psychological—are addressed concurrently, providing the best opportunity to mitigate the chronicity of CRPS, reduce its substantial burden, and enhance the patient's overall quality of life.

References:

1. Stanton-Hicks MD. CRPS: what's in a name? Taxonomy, epidemiology, neurologic, immune and autoimmune considerations. Reg Anesth Pain Med. 2019 Mar;44(3):376-387.
2. Goebel A. Complex regional pain syndrome in adults. Rheumatology (Oxford). 2011 Oct;50(10):1739-50.
3. Smart KM, Wand BM, O'Connell NE. Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst Rev. 2016 Feb 24;2(2):CD010853.
4. de Rooij AM, Perez RS, Huygen FJ, van Eijs F, van Kleef M, Bauer MC, van Hilten JJ, Marinus J. Spontaneous onset of complex regional pain syndrome. Eur J Pain. 2010 May;14(5):510-3.
5. Iolascon G, de Sire A, Moretti A, Gimigliano F. Complex regional pain syndrome (CRPS) type I: historical perspective and critical issues. Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(Suppl 1):4-10.
6. Shim H, Rose J, Halle S, Shekane P. Complex regional pain syndrome: a narrative review for the practising clinician. Br J Anaesth. 2019 Aug;123(2):e424-e433.

7. Harden NR, Bruehl S, Perez RSGM, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvanendran A, Mackey S, Graciosa J, Mogilevski M, Ramsden C, Chont M, Vatine JJ. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain. 2010 Aug;150(2):268-274.
8. Bruehl S. Complex regional pain syndrome. BMJ. 2015 Jul 29;351:h2730.
9. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010 Sep;113(3):713-25.
10. Galer BS, Henderson J, Perander J, Jensen MP. Course of symptoms and quality of life measurement in Complex Regional Pain Syndrome: a pilot survey. J Pain Symptom Manage. 2000 Oct;20(4):286-92.
11. Lohnberg JA, Altmaier EM. A review of psychosocial factors in complex regional pain syndrome. J Clin Psychol Med Settings. 2013 Jun;20(2):247-54.
12. Beerthuizen A, Stronks DL, Van't Spijker A, Yaksh A, Hanraets BM, Klein J, Huygen FJPM. Demographic and medical parameters in the development of complex regional pain syndrome type 1 (CRPS1): prospective study on 596 patients with a fracture. Pain. 2012 Jun;153(6):1187-1192.
13. Brunner F, Bachmann LM, Perez RSGM, Marinus J, Wertli MM. Painful swelling after a noxious event and the development of complex regional pain syndrome 1: A one-year prospective study. Eur J Pain. 2017 Oct;21(9):1611-1617.
14. Schürmann M, Gradl G, Zaspel J, Kayser M, Löhr P, Andress HJ. Peripheral sympathetic function as a predictor of complex regional pain syndrome type I (CRPS I) in patients with radial fracture. Auton Neurosci. 2000 Dec 28;86(1-2):127-34.
15. Geertzen JH, Dijkstra PU, Groothoff JW, ten Duis HJ, Eisma WH. Reflex sympathetic dystrophy of the upper extremity--a 5.5-year follow-up. Part I. Impairments and perceived disability. Acta Orthop Scand Suppl. 1998 Apr;279:12-8.
16. Puchalski P, Zyluk A. Complex regional pain syndrome type 1 after fractures of the distal radius: a prospective study of the role of psychological factors. J Hand Surg Br. 2005 Dec;30(6):574-80.
17. Rewhorn MJ, Leung AH, Gillespie A, Moir JS, Miller R. Incidence of complex regional pain syndrome after foot and ankle surgery. J Foot Ankle Surg. 2014 May-Jun;53(3):256-8. [
18. Jellad A, Salah S, Ben Salah Frih Z. Complex regional pain syndrome type I: incidence and risk factors in patients with fracture of the distal radius. Arch Phys Med Rehabil. 2014 Mar;95(3):487-92.
19. Ratti C, Nordio A, Resmini G, Murena L. Post-traumatic complex regional pain syndrome: clinical features and epidemiology. Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(Suppl 1):11-6.
20. Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain. 2003 May;103(1-2):199-207.
21. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007 May;129(1-2):12-20.
22. de Mos M, Huygen FJPM, Stricker CBH, Dieleman JP, Sturkenboom MCJM. The association between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain. 2009 Apr;142(3):218-224.
23. An HS, Hawthorne KB, Jackson WT. Reflex sympathetic dystrophy and cigarette smoking. J Hand Surg Am. 1988 May;13(3):458-60.
24. Goh EL, Chidambaram S, Ma D. Complex regional pain syndrome: a recent update. Burns Trauma. 2017;5:2.
25. Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002 Feb;11(1):47-51.
26. Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain. 2005 Aug;116(3):213-219.
27. Uçeyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. 2007 Nov;132(1-2):195-205.
28. Parkitny L, McAuley JH, Di Pietro F, Stanton TR, O'Connell NE, Marinus J, van Hilten JJ, Moseley GL. Inflammation in complex regional pain syndrome: a systematic review and meta-analysis. Neurology. 2013 Jan 01;80(1):106-17.
29. Leis S, Weber M, Schmelz M, Birklein F. Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome. Neurosci Lett. 2004 Apr 15;359(3):163-6.

30. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology. 2001 Dec 26;57(12):2179-84.
31. Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain. 2006 Mar-Apr;22(3):235-9.
32. Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett. 2008 Jun 06;437(3):199-202.
33. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, Kummer W, Birklein F, Vincent A, Goebel A, Wallukat G, Blaes F. Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain. 2011 Dec;152(12):2690-2700.
34. Dubuis E, Thompson V, Leite MI, Blaes F, Maihöfner C, Greensmith D, Vincent A, Shenker N, Kuttikat A, Leuwer M, Goebel A. Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. Pain. 2014 Nov;155(11):2408-17.
35. Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann Intern Med. 2010 Feb 02;152(3):152-8.
36. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous SM, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009 Oct;145(3):304-311.
37. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009 Dec 15;147(1-3):107-15.
38. Maihöfner C, Handwerker HO, Neundörfer B, Birklein F. Patterns of cortical reorganization in complex regional pain syndrome. Neurology. 2003 Dec 23;61(12):1707-15.
39. Maihöfner C, Handwerker HO, Neundörfer B, Birklein F. Cortical reorganization during recovery from complex regional pain syndrome. Neurology. 2004 Aug 24;63(4):693-701.
40. Pleger B, Tegenthoff M, Ragert P, Förster AF, Dinse HR, Schwenkreis P, Nicolas V, Maier C. Sensorimotor retuning [corrected] in complex regional pain syndrome parallels pain reduction. Ann Neurol. 2005 Mar;57(3):425-9.
41. Misidou C, Papagoras C. Complex Regional Pain Syndrome: An update. Mediterr J Rheumatol. 2019 Mar;30(1):16-25.
42. Terkelsen AJ, Mølgaard H, Hansen J, Finnerup NB, Krøner K, Jensen TS. Heart rate variability in complex regional pain syndrome during rest and mental and orthostatic stress. Anesthesiology. 2012 Jan;116(1):133-46.
43. Halicka M, Vittersø AD, Proulx MJ, Bultitude JH. Neuropsychological Changes in Complex Regional Pain Syndrome (CRPS). Behav Neurol. 2020;2020:4561831.
44. Libon DJ, Schwartzman RJ, Eppig J, Wambach D, Brahin E, Peterlin BL, Alexander G, Kalanuria A. Neuropsychological deficits associated with Complex Regional Pain Syndrome. J Int Neuropsychol Soc. 2010 May;16(3):566-73.
45. Park JY, Ahn RS. Hypothalamic-pituitary-adrenal axis function in patients with complex regional pain syndrome type 1. Psychoneuroendocrinology. 2012 Sep;37(9):1557-68.
46. Irwin DJ, Schwartzman RJ. Complex regional pain syndrome with associated chest wall dystonia: a case report. J Brachial Plex Peripher Nerve Inj. 2011 Sep 26;6:6.
47. Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009 May;25(4):273-80.
48. Chancellor MB, Shenot PJ, Rivas DA, Mandel S, Schwartzman RJ. Urological symptomatology in patients with reflex sympathetic dystrophy. J Urol. 1996 Feb;155(2):634-7.
49. Lee JW, Lee SK, Choy WS. Complex Regional Pain Syndrome Type 1: Diagnosis and Management. J Hand Surg Asian Pac Vol. 2018 Mar;23(1):1-10.
50. Nijs J, Kosek E, Van Oosterwijck J, Meeus M. Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? Pain Physician. 2012 Jul;15(3 Suppl):ES205-13.
51. Moseley GL, Flor H. Targeting cortical representations in the treatment of chronic pain: a review. Neurorehabil Neural Repair. 2012 Jul-Aug;26(6):646-52.
52. Smart KM, Ferraro MC, Wand BM, O'Connell NE. Physiotherapy for pain and

disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst Rev. 2022 May 17;5(5):CD010853.
53. O'Connell NE, Wand BM, McAuley J, Marston L, Moseley GL. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD009416.
54. Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial. QJM. 2006 Feb;99(2):89-95.
55. Kalita J, Misra U, Kumar A, Bhoi SK. Long-term Prednisolone in Post-stroke Complex Regional Pain Syndrome. Pain Physician. 2016 Nov-Dec;19(8):565-574.
56. Harden RN, McCabe CS, Goebel A, Massey M, Suvar T, Grieve S, Bruehl S. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition. Pain Med. 2022 Jun 10;23(Suppl 1):S1-S53.
57. Varenna M, Adami S, Sinigaglia L. Bisphosphonates in Complex Regional Pain syndrome type I: how do they work? Clin Exp Rheumatol. 2014 Jul-Aug;32(4):451-4.
58. Chevreau M, Romand X, Gaudin P, Juvin R, Baillet A. Bisphosphonates for treatment of Complex Regional Pain Syndrome type 1: A systematic literature review and meta-analysis of randomized controlled trials versus placebo. Joint Bone Spine. 2017 Jul;84(4):393-399.
59. Brown S, Johnston B, Amaria K, Watkins J, Campbell F, Pehora C, McGrath P. A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. Scand J Pain. 2016 Oct;13:156-163.
60. Zhu H, Wen B, Xu J, Zhang Y, Xu L, Huang Y. Efficacy and Safety of Pharmacological Treatment in Patients with Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel). 2024 Jun 20;17(6)
61. Kaye AD, Nguyen A, Boullion J, Blue MF, Allen DWH, Kelkar RA, Mouhaffel A, Ro AT, Ahmadzadeh S, Shekoohi S, Robinson CL. Efficacy of Immunotherapy for Complex Regional Pain Syndrome: A Narrative Review. Curr Pain Headache Rep. 2025 Jan 04;29(1):4.
62. Harden RN, Oaklander AL, Burton AW, Perez RS, Richardson K, Swan M, Barthel J, Costa B, Graciosa JR, Bruehl S., Reflex Sympathetic Dystrophy Syndrome Association. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. Pain Med. 2013 Feb;14(2):180-229.
63. O'Connell NE, Wand BM, Gibson W, Carr DB, Birklein F, Stanton TR. Local anaesthetic sympathetic blockade for complex regional pain syndrome. Cochrane Database Syst Rev. 2016 Jul 28;7(7):CD004598.
64. Huygen FJPM, Kallewaard JW, Nijhuis H, Liem L, Vesper J, Fahey ME, Blomme B, Morgalla MH, Deer TR, Capobianco RA. Effectiveness and Safety of Dorsal Root Ganglion Stimulation for the Treatment of Chronic Pain: A Pooled Analysis. Neuromodulation. 2020 Feb;23(2):213-221.
65. Deer TR, Levy RM, Kramer J, Poree L, Amirdelfan K, Grigsby E, Staats P, Burton AW, Burgher AH, Obray J, Scowcroft J, Golovac S, Kapural L, Paicius R, Kim C, Pope J, Yearwood T, Samuel S, McRoberts WP, Cassim H, Netherton M, Miller N, Schaufele M, Tavel E, Davis T, Davis K, Johnson L, Mekhail N. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017 Apr;158(4):669-681.
66. Zalewski A, Andreieva I, Wiśniowska J, Tarnacka B, Gromadzka G. Clinical and Molecular Barriers to Understanding the Pathogenesis, Diagnosis, and Treatment of Complex Regional Pain Syndrome (CRPS). Int J Mol Sci. 2025 Mar 11;26(6)
67. Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M. Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome? Pain. 2002 Jan;95(1-2):119-24.
68. Evaniew N, McCarthy C, Kleinlugtenbelt YV, Ghert M, Bhandari M. Vitamin C to Prevent Complex Regional Pain Syndrome in Patients With Distal Radius Fractures: A Meta-Analysis of Randomized Controlled Trials. J Orthop Trauma. 2015 Aug;29(8):e235-41.
69. Aïm F, Klouche S, Frison A, Bauer T, Hardy P. Efficacy of vitamin C in preventing complex regional pain syndrome after wrist fracture: A systematic review and meta-analysis. Orthop Traumatol Surg Res. 2017 May;103(3):465-470.